Skip to main content
Premium Trial:

Request an Annual Quote

23andMe Breast, Prostate, Colorectal Cancer PRS Reports

23andMe released three new polygenic risk score (PRS)-informed genetic reports on breast, colorectal, and prostate cancer. The reports aim to inform customers on whether they may have a relative increased likelihood of developing any of these conditions. The availability of the breast cancer and prostate cancer PRS reports depends on self-reported birth sex. The new reports neither diagnose, nor describe a person's overall likelihood for developing the conditions, and they do not include all genetic variants, including those linked to hereditary cancer syndromes, that may be associated with risks for these conditions. The colorectal cancer report is currently only available for individuals of European and Latino/Hispanic descent, as there is not yet enough data to provide a result for other genealogical ancestries. The PRS models underpinning the new reports were developed using the 23andMe database and validated using an external database.